Aurinia Pharmaceuticals (AUPH) PT Lowered to $22 at RBC Capital
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $15.47 +1.91%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $22.00 (from $27.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Diversified Royalty Corp (DIV:CN) (BEVFF) PT Lowered to Cdn$4.75 at Desjardins
- Calian Group Ltd (CGY:CN) (CLNFF) PT Raised to Cdn$109 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
